EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Impact and Effectiveness of COVID ‐19 mRNA Vaccination Against COVID ‐19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain

Belén Castillo-Cano iD, Fabio Riefolo, Felipe Villalobos, Mar Martín-Pérez, Davide Messina, Roel Elbers, Dorieke Brink-Kwakkel, Carlo Alberto Bissacco, Elena Segundo, Luis Carlos Saiz, Leire Leache, Elisa Barbieri und 4 weitere

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70239 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Belén Castillo-Cano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Medicines Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Despite Spain's > 2 million COVID‐19 paediatric cases before 2024, few required hospitalisations (8900). We aimed to estimate the effectiveness of two‐dose COVID‐19 vaccinations against hospitalisation ‘with’ and ‘for’ COVID‐19 in paediatrics.

Methods

All individuals aged 5–14 years between January 2021 and February 2022 in two databases in Spain (SIDIAP and BIFAP) vaccinated against COVID‐19 (two doses) were matched 1:1 to unvaccinated controls with the same age, sex, region and comorbidities on the dates of vaccination. Individuals with previous SARS‐CoV‐2 infections were excluded. COVID‐19 was identified as the main reason (hospitalisation ‘for’ COVID‐19; SIDIAP) or as one of the reasons (hospitalisation ‘with’ COVID‐19; BIFAP) for hospitalisation with a positive SARS‐CoV‐2 test ±30 days. Incidence rate differences and vaccine effectiveness (VE; 95% CI; controlled by inverse probability weights) against hospitalisations ‘for’ and ‘with’ COVID‐19 were calculated.

Results

The cohorts included 75 361 (SIDIAP) and 178 589 (BIFAP) pairs. Among vaccinated individuals (99.99% with mRNA vaccines) and controls, < 5 and 15 hospitalisations ‘for’ COVID‐19 were identified (SIDIAP), whereas 21 and 32 hospitalisations ‘with’ COVID‐19 (BIFAP), all aged 12–14 years old. Vaccination prevented 2.5 hospitalisations ‘for’ and 0.5 ‘with’ COVID‐19 during the Delta period, and 0.8 hospitalisations ‘with’ COVID‐19 during Omicron predominance per 10 6 person‐days. The VE was 94% (95% CI: 52%–99%; SIDIAP) and 53% (95% CI: 18%–74%; BIFAP).

Conclusions

Given the low incidence of hospitalised COVID‐19, two‐dose series mRNA vaccination showed moderate‐high effectiveness with few averted cases. Including hospitalisation ‘with’ COVID‐19 underestimated the effectiveness. If paediatric severe COVID‐19 remains rare, larger databases are required to understand precisely the effectiveness and impact of new vaccines. Trial Registration: EU PAS Register number: EUPAS47725

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationCOVID-19 VaccinesVaccine EfficacyHumansChildAdolescentSpainMaleFemaleChild, PreschoolCohort StudiesVaccinationDatabases, FactualSARS-CoV-2mRNA VaccinesInformation Sources

Stichwörter der Autor:innen

COVID‐19 vaccine effectivenesschildren and adolescentshospital COVID‐19 recordspaediatricsreal‐word dataretrospective cohort study

Substanzen

COVID-19 VaccinesmRNA Vaccines

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain.
  • VAccine Monitoring Collaboration for Europe, Brussels, Belgium.
  • Teamit Institute, Partnership, Barcelona Health Hub, Barcelona, Spain.
  • Fundació Institut Universitari per a la Recerca a L'atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Agenzia Regionale di Sanita' Toscana, Florence, Italy.
  • Department of Data Science and Biostatistics, University Medical Center Utrecht, Utrecht, the Netherlands.

ORCID-Profile: Belén Castillo-Cano, Rosa Gini, Elisa Martín-Merino

Förderung

  • European Medicines Agency

Zitieren

APA

Castillo-Cano, B., Riefolo, F., Villalobos, F., Martín-Pérez, M., Messina, D., Elbers, R., Brink-Kwakkel, D., Bissacco, C. A., Segundo, E., Saiz, L. C., Leache, L., Barbieri, E., Vaz, T., Gini, R., Klungel, O., & Martín-Merino, E. (2025). Impact and Effectiveness of COVID ‐19 mRNA Vaccination Against COVID ‐19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70239

Vancouver

Castillo-Cano B, Riefolo F, Villalobos F, Martín-Pérez M, Messina D, Elbers R, et al. Impact and Effectiveness of COVID ‐19 mRNA Vaccination Against COVID ‐19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70239

BibTeX
@article{CastilloCano2025,
  author = {Castillo-Cano, Belén and Riefolo, Fabio and Villalobos, Felipe and Martín-Pérez, Mar and Messina, Davide and Elbers, Roel and Brink-Kwakkel, Dorieke and Bissacco, Carlo Alberto and Segundo, Elena and Saiz, Luis Carlos and Leache, Leire and Barbieri, Elisa and Vaz, Tiago and Gini, Rosa and Klungel, Olaf and Martín-Merino, Elisa},
  title = {Impact and Effectiveness of COVID ‐19 mRNA Vaccination Against COVID ‐19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70239}
}
Kostenlos starten →